68 Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months ... Peter MacCallum Cancer Centre, Melbourne, Australia.

supporting NUCLIDIUM's path towards commercialising its theranostic products. "61Cu-NuriPro enters Phase I trial for prostate ...

Michael Morris, MD, says the new technology provides a major step forward in diagnosing and treating prostate ... the cancer cell. Michael began treatment in July 2019 and finished in February 2020.

The success of SARTATE will pave the way for the broad use of SAR Technology to improve the diagnosis and treatment of prostate cancer, breast cancer and other types of solid tumors, and ...

Theranostic molecules are suitable for diagnosis and therapy of cancers. “From a clinical perspective, PSMA is a valuable target for diagnosis and therapy of prostate cancer,” commented ...

MOVING GIF: 68G a-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months ... Peter MacCallum Cancer Centre, Melbourne, Australia.